Sparrow Pharmaceuticals
CompanyUnited States
Sparrow Pharmaceuticals develops one asset, in phase 2 (clofutriben in cortisol excess). Mostly small molecule acting on lipid and ceramide metabolism and HSD11B1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 3
- Trials
- 0
- Signals
Pipeline
1Inhibitor of 11beta-hydroxysteroid dehydrogenase type 1, lowering intracellular cortisol regeneration.
Phase 2, Small molecule, Lipid and ceramide metabolism, HSD11B1, cortisol excess, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials3
- Signals4
- Similar companies6